Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
29.64
-0.55 (-1.82%)
At close: Mar 17, 2026, 4:00 PM EDT
29.06
-0.58 (-1.96%)
After-hours: Mar 17, 2026, 5:39 PM EDT
Celldex Therapeutics Revenue
In the year 2025, Celldex Therapeutics had annual revenue of $1.55M, down -77.99%. Celldex Therapeutics had revenue of $121.00K in the quarter ending December 31, 2025, a decrease of -89.70%.
Revenue (ttm)
$1.55M
Revenue Growth
-77.98%
P/S Ratio
1,277.04
Revenue / Employee
$7,803
Employees
198
Market Cap
1.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55M | -5.48M | -77.99% |
| Dec 31, 2024 | 7.02M | 136.00K | 1.98% |
| Dec 31, 2023 | 6.88M | 4.53M | 192.07% |
| Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
| Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
| Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
| Dec 31, 2019 | 3.57M | -5.97M | -62.54% |
| Dec 31, 2018 | 9.54M | -3.21M | -25.15% |
| Dec 31, 2017 | 12.74M | 5.96M | 87.78% |
| Dec 31, 2016 | 6.79M | 1.31M | 23.83% |
| Dec 31, 2015 | 5.48M | 1.89M | 52.82% |
| Dec 31, 2014 | 3.59M | -525.00K | -12.77% |
| Dec 31, 2013 | 4.11M | -7.09M | -63.30% |
| Dec 31, 2012 | 11.20M | 1.94M | 20.91% |
| Dec 31, 2011 | 9.27M | -37.53M | -80.20% |
| Dec 31, 2010 | 46.79M | 31.61M | 208.25% |
| Dec 31, 2009 | 15.18M | 7.72M | 103.59% |
| Dec 31, 2008 | 7.46M | 6.05M | 430.30% |
| Dec 31, 2007 | 1.41M | 506.82K | 56.36% |
| Dec 31, 2006 | 899.18K | -2.19M | -70.88% |
| Dec 31, 2005 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 673.00M |
| Zai Lab | 460.16M |
| Aurinia Pharmaceuticals | 283.06M |
| Adaptive Biotechnologies | 276.98M |
| Stoke Therapeutics | 205.63M |
| Syndax Pharmaceuticals | 172.35M |
| Nektar Therapeutics | 55.23M |
CLDX News
- 18 days ago - Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 - GlobeNewsWire
- 20 days ago - Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 20 days ago - Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria - GlobeNewsWire
- 22 days ago - Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile - GlobeNewsWire
- 5 weeks ago - Celldex to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - MoneyShow's Best Investment Ideas For 2026: Part 3 - Seeking Alpha
- 3 months ago - Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism - GlobeNewsWire
- 4 months ago - Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer - GlobeNewsWire